EyeBio CEO David Guyer (L) and CSO Anthony Adamis
November 14, 2023 10:40 AM ESTUpdated 12:06 PM
Financing
Startups

Eye­Bio dou­bles the size of its Se­ries A as an­ti-VEGF vet­er­ans seek new ways of treat­ing reti­nal dis­eases

Kyle LaHucik

Senior Reporter

Reti­nal dis­ease biotech Eye­Bio has dou­bled the size of its ini­tial Se­ries A raise from Feb­ru­ary 2022. With an­oth­er $65 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times